share_log

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $17

Benzinga ·  Oct 5, 2023 14:30

Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $20 to $17.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment